SARC046

A Phase II Trial of Nab-Sirolimus in Patients With Progressing or Symptomatic Epithelioid Hemangioendothelioma

TYPE OF SARCOMA: Epithelioid Hemangioendothelioma
DRUG: nab-Sirolimus

ACCRUAL STATUS: Now recruiting patients

OVERALL STUDY PRINCIPAL INVESTIGATOR:
Michael Wagner, MD, Dana-Farber Cancer Institute

CLINICALTRIALS.GOV IDENTIFIER: NCT06942442
FOR STUDY DETAILS AND ELIGIBILITY CRITERIA: CLINICAL TRIALS

To contact the study research staff: